Pangea Laboratory

Pangea Laboratory is a U.S.-based diagnostic services company founded in 2019, operating a high-complexity clinical lab. It provides end-to-end NGS services from R&D through commercialization, serving as a development and reference lab partner. The company has a growing menu of proprietary non-invasive tests, including an FDA Breakthrough Device-designated assay for bladder cancer, and is expanding into microbiome and infectious disease diagnostics. Its business model combines fee-for-service lab work with the development and launch of its own diagnostic products.

CLIA/CAP-accredited next-generation sequencing (NGS) and molecular diagnostics lab with advanced bioinformatics, specializing in non-invasive sample testing and end-to-end assay development from R&D to commercialization.

Pangea competes with large national reference laboratories (Quest Diagnostics, LabCorp), specialty oncology diagnostics companies (Exact Sciences, Guardant Health), and numerous other CLIA labs offering NGS services. Differentiation is achieved through its focus on non-invasive testing, end-to-end development partnership model, and a targeted pipeline in urologic oncology and clinical microbiology.